Can-Fite BioPharma (CANF) has released an update.
Can-Fite BioPharma Ltd., an Israeli biopharmaceutical company, has announced the ongoing offer and sale of up to $9 million in American Depositary Shares (ADSs), each representing 300 ordinary shares. The offering is being carried out under an At The Market Offering Agreement and a previously filed Registration Statement with the SEC. Legal counsel has confirmed that upon issuance, the ordinary shares underlying the ADSs will be validly issued, fully paid, non-assessable, and free of preemptive or similar rights.
For further insights into CANF stock, check out TipRanks’ Stock Analysis page.
